Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.

A, Tfayli; Assaad M, Al; G, Fakhri; R, Akel; H, Atwi; H, Ghanem; Karak F, El; F, Farhat; Rabi K, Al; P, Sfeir; P, Youssef; Z, Mansour; H, Assi; M, Haidar; Ghanem A, Abi; I, Khalifeh; F, Boulos; R, Mahfouz; B, Youssef; Y, Zeidan; R, Bejjany; F, Khuri

doi:10.1002/cam4.3456

Public

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.

Shared by NobleBlocks on Sep 29, 2020 • 12:00 AM UTC

Authors:

Tfayli A

Al Assaad M

Fakhri G

Abstract

Multiple randomized studies have shown that combination of chemotherapy and immune checkpoint inhibitors (ICIs) leads to better response rates and survival as compared to chemotherapy alone in the advanced stage of NSCLC. Data suggesting a benefit to using ICIs in the neoadjuvant therapy of patients...

Subject

Neoadjuvant Therapy

Nonsmall Cell Lung Cancer

Oncogenic Drivers

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!